中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2011年
14期
63-65
,共3页
心房颤动%胺碘酮%螺内酯%厄贝沙坦
心房顫動%胺碘酮%螺內酯%阨貝沙坦
심방전동%알전동%라내지%액패사탄
Atrial fibrillation%Amiodarone%Spironolactone%Irbesartan
目的 评价螺内酯、厄贝沙坦联合胺碘酮治疗阵发性心房颤动的疗效.方法 将123例阵发性心房颤动患者随机分为胺碘酮+螺内酯组(A组n=41)、胺碘酮+厄贝沙坦组(B组n=41)、胺碘酮+螺内酯+厄贝沙坦组(C组n=41),随访1.5年,研究的一级终点为房颤复发.比较三组治疗后的窦性心律维持率以及治疗前后、6、12、18个月的左心房内经.结果 试验终点时,窦性心律维持率:A组70.0%、B组69.2%、C组87.5%,A组、B组比较差异无统计学意义,C组与A、B两组比较差异有统计学意义(P＜0.05).A、B两组左房内径大于C组,但差异无统计学意义.结论 螺内酯、厄贝沙坦单药加胺碘酮治疗阵发性心房颤动在维持窦性心律方面具有相同的疗效,但两药联合优于单药疗效,并能进一步抑制左心房的扩大.
目的 評價螺內酯、阨貝沙坦聯閤胺碘酮治療陣髮性心房顫動的療效.方法 將123例陣髮性心房顫動患者隨機分為胺碘酮+螺內酯組(A組n=41)、胺碘酮+阨貝沙坦組(B組n=41)、胺碘酮+螺內酯+阨貝沙坦組(C組n=41),隨訪1.5年,研究的一級終點為房顫複髮.比較三組治療後的竇性心律維持率以及治療前後、6、12、18箇月的左心房內經.結果 試驗終點時,竇性心律維持率:A組70.0%、B組69.2%、C組87.5%,A組、B組比較差異無統計學意義,C組與A、B兩組比較差異有統計學意義(P＜0.05).A、B兩組左房內徑大于C組,但差異無統計學意義.結論 螺內酯、阨貝沙坦單藥加胺碘酮治療陣髮性心房顫動在維持竇性心律方麵具有相同的療效,但兩藥聯閤優于單藥療效,併能進一步抑製左心房的擴大.
목적 평개라내지、액패사탄연합알전동치료진발성심방전동적료효.방법 장123례진발성심방전동환자수궤분위알전동+라내지조(A조n=41)、알전동+액패사탄조(B조n=41)、알전동+라내지+액패사탄조(C조n=41),수방1.5년,연구적일급종점위방전복발.비교삼조치료후적두성심률유지솔이급치료전후、6、12、18개월적좌심방내경.결과 시험종점시,두성심률유지솔:A조70.0%、B조69.2%、C조87.5%,A조、B조비교차이무통계학의의,C조여A、B량조비교차이유통계학의의(P＜0.05).A、B량조좌방내경대우C조,단차이무통계학의의.결론 라내지、액패사탄단약가알전동치료진발성심방전동재유지두성심률방면구유상동적료효,단량약연합우우단약료효,병능진일보억제좌심방적확대.
Objective To evaluate the clinical efficacy of spironolactone or/and irbesartan in combination with amiodarone on maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation(PAF). Methods One hundred and twenty-three patients with PAF were included in the study and randomly divided into three groups: group A (spironolactone plus amiodarone, n=41); group B (irbesartan plus amiodarone, n=41); group C (spironolactone and irbesartan plus amiodarone, n=41). The left atrial diameter (LAD) was measured with transthoracic echocardiogram at before and after 6,12 and 18 month of treatment. The duration of observation was up to one and half years and the primary end point of the study was the first recurrence of AF. Results At the end of the study, the maintenance of sinus rhythm in group C was higher significantly than that in group A and group B (87.5% vs 70.0% and 69.2%, P＜0.05).Nevertheless, there was no significant difference between group A and group B. LAD in group A and group B was larger than that in group C. Conclusions Amiodarone with spironolactone or irbesartan is the same clinical efficacy in sinus rhythm maintenance for PAF. The combination of spironolactone with irbesartan is more effective than monotherapy, and could inhibit the enlargement of left atrium and reduce recurrence rate in patients with PAF.
